[HTML][HTML] Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Importance Patients with cancer have an increased risk of severe disease and mortality from
COVID-19, as the disease and antineoplastic therapy cause reduced vaccine …
COVID-19, as the disease and antineoplastic therapy cause reduced vaccine …
mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer
mRNA vaccines have evolved as promising cancer therapies. These vaccines can encode
tumor-allied antigens, thus enabling personalized treatment approaches. They can also …
tumor-allied antigens, thus enabling personalized treatment approaches. They can also …
Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19
S Haggenburg, Q Hofsink, BI Lissenberg-Witte… - JAMA …, 2022 - jamanetwork.com
Importance It has become common practice to offer immunocompromised patients with
hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are …
hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are …
Omicron-specific cytotoxic T-cell responses after a third dose of mRNA COVID-19 vaccine among patients with multiple sclerosis treated with ocrelizumab
N Madelon, N Heikkilä, IS Royo, P Fontannaz… - JAMA …, 2022 - jamanetwork.com
Importance The SARS-CoV-2 variant B. 1.1. 529 (Omicron) escapes neutralizing antibodies
elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is …
elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is …
[HTML][HTML] Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
A Keppler-Hafkemeyer, C Greil, PR Wratil… - Nature Cancer, 2023 - nature.com
Individuals with hematologic malignancies are at increased risk for severe coronavirus
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
Y Shen, JA Freeman, J Holland, K Naidu… - Blood, The Journal …, 2022 - ashpublications.org
Patients with chronic lymphocytic leukemia (CLL) or monoclonal B-lymphocytosis (MBL)
have impaired response to COVID-19 vaccination. A total of 258 patients (215 with CLL and …
have impaired response to COVID-19 vaccination. A total of 258 patients (215 with CLL and …
Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies
Background Patients with hematologic malignancies have impaired humoral immunity
secondary to their malignancy and its treatment, placing them at risk of severe coronavirus …
secondary to their malignancy and its treatment, placing them at risk of severe coronavirus …
[HTML][HTML] Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review
Background Patients living with cancer are at a significantly increased risk of morbidity and
mortality after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV …
mortality after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV …
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on …
A Visentin, T Chatzikonstantinou… - American journal of …, 2023 - Wiley Online Library
In this retrospective international multicenter study, we describe the clinical characteristics
and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders …
and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders …
[HTML][HTML] Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients …
N Uaprasert, P Pitakkitnukun… - Blood Cancer …, 2022 - nature.com
Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …